

Cancer - RET positive

## How does the body process a cancer medicine (pralsetinib) – when it is taken together with another medicine (cyclosporine)

<b>Trial Status</b> Completed	<b>Trial Runs In</b> 1 Countries	<b>Trial Identifier</b> GP43162
----------------------------------	-------------------------------------	------------------------------------

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This clinical trial was done to study a medicine called, “pralsetinib”, for the treatment of patients with some types of cancer. The main questions were 1) What was the the effect of a single dose of cyclosporine on a single dose of pralsetinib? 2) How safe was it to give pralsetinib with cyclosporine – in comparison to giving pralsetinib alone? Fifteen healthy people took part in this study at one study center in one country.

<b>F. Hoffmann-La Roche Ltd (Switzerland)</b> Sponsor	<b>Phase 1</b> Phase
--	-------------------------

---

**GP43162**  
Trial Identifiers

---

### *Eligibility Criteria:*

<b>Gender</b> All	<b>Age</b> 18 to 55 years	<b>Healthy Volunteers</b> Yes
----------------------	------------------------------	----------------------------------

---

Fifteen healthy volunteers were enrolled at one study site in USA to evaluate the effect of coadministration of cyclosporine on the pharmacokinetics of pralsetinib in healthy males and females of non-childbearing potential. Thirteen participants completed the study. Results showed that coadministration of cyclosporine and pralsetinib increased exposure to pralsetinib and increased the highest concentration of pralsetinib reached post-dosing. There were no deaths or serious side effects. The data from this study will help support further development of pralsetinib.